Due to the rising need for non-invasive imaging techniques for drug development, disease diagnostics, and research, the global preclinical imaging market has enormous potential. The preclinical imaging market has been expanding consistently and is likely to keep doing so in the years to come. The market had a value of US$ 1,873.6 million in 2022, and it is likely to increase at a compound annual growth rate (CAGR) of 5.6% from 2022 to 2031, reaching a valuation of US$ 3,011.7 million by 2031.
Request Sample Copy of Research Report @ https://www.astuteanalytica.com/request-sample/preclinical-imaging-market
Preclinical imaging is essential to the development of contemporary pharmaceuticals. It enables scientists to take high-resolution, real-time images of the living body without endangering the individual. Scientists now have access to previously unobtainable information about how diseases originate and how new treatments might create to combat them. Preclinical imaging is now used on larger animal models, even human patients, in addition to more conventional small animal models.
Preclinical imaging is now utilized across the whole drug development process, from lead optimization and efficacy testing to target identification and validation. Additionally, it is becoming more and more significant in clinical decision-making as more and more medications are being created with personalized medicine in mind. Preclinical imaging is increasingly employed for functional applications, including receptor occupancy studies, safety pharmacology, and toxicological evaluations, in addition to its traditional usage.
Significant improvements in imaging technologies, including MRI, CT, PET, and optical imaging, are being seen in the preclinical imaging sector. Preclinical imaging is now a more dependable tool for research and development due to improvements in imaging quality, resolution, and sensitivity brought about by these developments. the introduction of new and enhanced imaging modalities such as multimodal imaging, molecular imaging, and functional imaging has increased the range of preclinical imaging applications. For instance, while functional imaging enables the study of physiological processes in real-time, molecular imaging enables the visualization of molecular and cellular activities. As a result, preclinical imaging technology advances will likely continue to spur market expansion by enhancing the precision of preclinical imaging and broadening its scope of applications.
Europe accounts for 29% of the share and is the second-largest market.
North America is likely to hold a revenue share of over 44% in the preclinical imaging market, followed by Europe, with a revenue share of over 29% due to a number of things, including the region’s high need for improved imaging technologies, the high prevalence of chronic diseases, and increased funding in preclinical research.
The European Commission has proposed new legislation that would make it simpler for small enterprises to acquire funding. Thus, this could encourage more innovation in the industry. Additionally, a lot of the biggest businesses in the sector are spending a lot of money on research and development in the hopes of developing new goods that will help sales rebound.
To gain more insights into the market with a detailed table of content and figures, click here: https://www.astuteanalytica.com/industry-report/preclinical-imaging-market
Companies Profile
In order to further scientific research, General Electric, and Siemens Healthineers provide top-notch solutions in the global preclinical imaging market. These businesses dominate this market with a combined market share of more than 50%, making them the undisputed leaders.
In addition, other key competitors are using strategies to grow and be in the competition. For instance, in May 2022, Bruker for its line of market-dominant preclinical magnetic resonance imaging (MRI) systems, introduced innovating 7 Tesla and 9.4 Tesla conduction-cooled Maxwell magnets. The new line of Maxwell 7 Tesla and 9.4 Tesla magnets, which follow the success of its BioSpec® Maxwell 3 Tesla model, eliminates the requirement for liquid Helium or Nitrogen refills while providing high-field sensitivity and resolution for cutting-edge preclinical MRI and PET/MR research.
In May 2022, Vevo® F2, the first ultra-high to low frequency (71MHz-1MHz) ultrasound and photoacoustic imaging system in the world for preclinical application, was introduced by a global pioneer in ultra-high frequency ultrasound and photoacoustic imaging systems.
Segmentation Analysis
Pharmaceutical and biotech companies are the leading consumers of the Preclinical Imaging Market.
Pharmaceutical companies use preclinical imaging as a key tool when developing novel medications and treatments. It makes it possible to see how biological functions operate in living creatures, giving important details on effectiveness and security. As more businesses look to acquire a competitive edge in drug development, there has been a considerable increase in the demand for preclinical imaging services in recent years.
The market is growing owing to the rising investments in R&D by biotech companies, notably in the areas of drug discovery and development. Preclinical imaging is essential in the early stages of drug development, which is a focus of biotech businesses. These companies are working to provide new medications and treatments for a range of illnesses and disorders.
During the projection period, research and development are likely to hold a market share of over 58%. This is due to the rise in the need for preclinical imaging technologies for R&D tasks in the pharmaceutical and biotechnology sectors. Researchers can assess the safety and effectiveness of new medications early in the drug development process by using preclinical imaging to see and monitor biological processes.
Key Players:
- Agilent Technologies
- Bruker Corporation
- Canon
- Fujifilm Corporation
- General Electric (GE)
- Hitachi, Ltd.
- Hologic
- Konica Minolta, Inc.
- Koninklijke Philips
- Mediso Limited
- MILabs B.V.
- Molecubes
- MR Solutions
- PerkinElmer, Incorporated
- Siemens Healthineers
- TriFoil Imaging
- Varex Imaging
- Other Prominent Players
Segmentation Outline
By Type
- Products
-
- Instruments
- Reagents
- Software Tools
- Imaging Services
By Product
- CT Imaging
- Optical Imaging
- Ultrasound Imaging
- MRI Imaging
- PET/SPECT Imaging
- Others
By Application
- Research and Development
- Drug Discovery
By End User
- Biotech Companies
- Research Institutes
- Pharmaceutical Companies
By Distribution Channel
- Online
- Offline
By Region
- North America
-
- The U.S.
- Canada
- Mexico
- Europe
- Western Europe
-
-
- The UK
- Germany
- France
- Italy
- Spain
- Rest of Western Europe
-
- Eastern Europe
-
- Poland
- Russia
- Rest of Eastern Europe
-
- Asia Pacific
- China
- India
- Japan
- Australia & New Zealand
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- Saudi Arabia
- South Africa
- UAE
- Rest of MEA
- South America
- Argentina
- Brazil
- Rest of South America
Directly Purchase a copy of report with TOC @ https://www.astuteanalytica.com/inquire-before-purchase/preclinical-imaging-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company which has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
Contact us:
Aamir Beg
BSI Business Park, H-15,Sector-63, Noida- 201301- India
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
Email: sales@astuteanalytica.com
Website: www.astuteanalytica.com